Biotech Startup Spartina Biotechnologies, Now Known as Mercury Bio
Biotech Startup Spartina Biotechnologies, Now Known as Mercury Bio
A Santa Fe-based biotech startup, Spartina Biotechnologies, recently reported a raise of just over $1 million — this time under a new name, Mercury Bio.
Previously known as Spartina Biotechnologies, Mercury Bio Inc. is the new name of the joint venture created by a few well-known bioscience founders in New Mexico. The startup has raised $1.15 million of a $3 million offering, according to a Feb. 16 U.S. Securities and Exchange Commission filing.
Originally called Spartina Biotechnologies, the company changed its name to Mercury Bio in 2022 to reflect their rapidly increasing focus on molecular drug-delivery technologies. Like the Roman god Mercury, Mercury Bio aims to be a messenger and translator, delivering targeted genetic information to regulate events at the cellular level, translating disease into health.
What does Mercury Bio do? Mercury Bio is developing a next-generation biomolecular drug delivery platform due to scientific breakthroughs in genomic research.
RNA and small-molecule drugs can be delivered by Mercury Bio’s platform through highly specific cell targeting without creating an immune reaction. Their platform will allow drug developers to speed their products to market by reducing the obstacles and risks encountered by traditional drug delivery systems. Low cost, speed to market, and high targeting will, most importantly, dramatically improve patient outcomes.
Mercury Bio is supported by the New Mexico Consortium.
See the entire article at: Santa Fe biotech startup raises $1M under new company name.